Hung-Kai Kevin Chen, MD, PhD

Dr. Hung-Kai Kevin Chen is a physician-scientist, biotech entrepreneur, and pharmaceutical executive with over 25 years of experience in biomedical research, translational medicine, and innovative drug development. As the Founder, Chairman, CEO, and Chief Medical Officer of Elixiron Immunotherapeutics, he leads the development of next-generation precision immunotherapies targeting autoimmune and neurodegenerative diseases.

Under his leadership, Elixiron has advanced two potentially first-in-class therapeutics into Phase II clinical development for Alzheimer’s disease and vitiligo, and successfully achieved a public listing on the Taipei Exchange Emerging Stock Board (ESB) in January 2026. Dr. Chen is also the Founder and CEO of NeuroVantix Therapeutics, a Houston-based biotechnology startup focused on developing innovative therapies for neurodegenerative diseases. His contributions to innovative drug discovery have been recognized internationally, including two prestigious Alzheimer’s Association Part the Cloud Awards (2020 and 2022) and Taiwan’s National Innovation Award (2020).

Prior to founding Elixiron, Dr. Chen held senior scientific and executive positions at GSK, the Gladstone Institutes, the Development Center for Biotechnology, and Eusol Biotech. He completed his postdoctoral training at Baylor College of Medicine and the Howard Hughes Medical Institute and holds MD and PhD degrees from National Yang-Ming University.

Dr. Chen has authored numerous scientific publications in leading journals, including Cell, Nature Medicine, and Cancer Discovery. His career bridges academic discovery, pharmaceutical innovation, and biotech entrepreneurship, with a focus on translating breakthrough science into transformative medicines.